Antiviral Drugs - Switzerland | Statista Market Forecast

In Switzerland, the Antiviral Drugs market is estimated to witness a substantial growth in revenue, with projections indicating a significant increase to reach US$278.50m by the year 2024.
Furthermore, it is anticipated that the market will continue to expand steadily, displaying an annual growth rate (CAGR 2024-2029) of 1.67%.
As a result, the market volume is predicted to reach US$302.50m by 2029.
When compared to other countries worldwide, it is noteworthy that United States is expected to generate the highest revenue in the Antiviral Drugs market, amounting to US$30.64bn in 2024.
This demonstrates the significant market potential and demand for Antiviral Drugs market United States.
Switzerland, a global leader in pharmaceuticals, is pioneering innovative antiviral drugs to combat emerging viral threats.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

The Antiviral Drugs market in Switzerland has been experiencing some interesting trends in the recent past.

Customer preferences: Switzerland is known for its high-quality healthcare system, and the demand for antiviral drugs is no exception. The Swiss population is highly aware of the importance of preventive healthcare, and as a result, there is a growing demand for antiviral drugs. Additionally, the aging population in Switzerland is also contributing to the growth of the antiviral drugs market, as older people are more susceptible to viral infections.

Trends in the market: One of the major trends in the antiviral drugs market in Switzerland is the increasing demand for combination therapies. Combination therapies involve the use of two or more antiviral drugs to treat a viral infection, and they have been shown to be more effective than single-drug therapies. Another trend in the market is the growing use of generic antiviral drugs. Generic drugs are more affordable than their branded counterparts, and as a result, they are becoming increasingly popular among Swiss consumers.

Local special circumstances: Switzerland has a highly regulated healthcare system, which has both advantages and disadvantages for the antiviral drugs market. On the one hand, the strict regulations ensure that only high-quality drugs are sold in the market, which is good news for consumers. On the other hand, the regulations make it difficult for new entrants to enter the market, which can stifle competition and lead to higher prices for consumers.

Underlying macroeconomic factors: The Swiss economy is known for its stability and affluence, which has a positive impact on the antiviral drugs market. The high disposable income of Swiss consumers means that they are willing to pay a premium for high-quality drugs, which is good news for pharmaceutical companies. Additionally, the strong Swiss franc makes it easier for Swiss consumers to purchase drugs from other countries, which can increase competition in the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.